clinical trial · NCT06633757
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
Primary Ciliary Dyskinesia (PCD)RCT1100
brief summary
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
started
Oct 22, 2024
primary completion
Jun 30, 2025
completion
Dec 30, 2025
last updated
Oct 20, 2025
detailed description
The primary objective of this study is to determine the impact of multiple doses of inhaled RCT1100, administered via nebulizer, on MCC with adult participants with Primary Ciliary Dyskinesia caused by pathogenic mutations in the DNAI1 Gene.
official title
A Phase 1b, Open-label, Study of RCT1100 in Adults With Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance and Other Measures of Pharmacodynamic Activity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol